Status: Recruiting
Semaglutide Delivered Epi-Intradermally by Microarray Patch (VX-201) Versus Subcutaneous Administration in Healthy Overweight and Obese Participants
VX-201-101 is a first-in-human Phase 1 clinical study evaluating VX-201, a needle-free microneedle (MN) array patch (MAP) that delivers semaglutide through the skin as an alternative to subcutaneous (SC) injection.
Participants needed: 62
Trial details
Phase: Phase 1Age: 18-60Biological sex: AllType: InterventionalSponsor: Terrestrial Bio, Inc.Updated: Jun 29, 2026Locations: 1
Eligibility criteria
Medically healthy with no clinically significant medical history, vital sign, or... [+3]
Any disorder which in the investigator's opinion might jeopardize the subject's... [+22]